CAMPBELL, Calif., Jan. 8, 2020 /PRNewswire/ — KDx Diagnostics, Inc. (KDx), announced today that the Food and Drug Administration (FDA) has granted “Breakthrough Device” designation for its URO17™ Bladder Cancer Recurrence Test … Read More

Bladder carcinoma is a common urological cancer with high morbidity, mortality, and recurrence rates requiring frequent, invasive diagnostic procedures Read More 1, Read More 2

A new biomarker allows effective, noninvasive screening of patients at risk of the disease. Bladder cancer presents a diagnostic challenge for even the best pathologists and laboratory medicine professionals Read More

PLAINVIEW, N.Y. and CAMPBELL, Calif., July 25, 2019 /PRNewswire/ — Acupath Laboratories, Inc., a leading provider of sub-specialized anatomic and molecular pathology services, and KDx Diagnostics, Inc., a leading developer of bladder cancer tests, today announced that KDx has licensed Acupath to incorporate its URO17™ … Read More

Cytology and cystoscopy have limited sensitivity and specificity for the diagnosis of urothelial carcinoma ( due to inflammatory atypia, sampling errors, and other clinicopathologic factors that may … Read More

There is a clinical need to identify novel biomarkers to improve diagnostic accuracy for the detection of urothelial tumors. The current study aimed to evaluate keratin 17 (K17), an oncoprotein that drives cell cycle progression in cancers … Read More